Velosity (Graham Partners portfolio) Acquires Lucid Labs

Paylocity Acquires Grayscale Labs

April 11, 2026

AI & Machine Learning

Paylocity announced it has acquired Grayscale Labs to strengthen its AI-powered recruiting capabilities, especially for high-volume hiring organizations. The acquisition will integrate Grayscale’s recruiting automation technology into Paylocity’s human capital management platform to help employers engage candidates earlier and move faster through recruiting workflows.

Madison Bidco Ltd (consortium led by Lightrock, Carbon Direct Capital, GenZero and Kibo) to Acquire Velocys

December 6, 2023

Renewable Energy

Madison Bidco Ltd., a newly formed acquisition vehicle indirectly owned by a consortium including Lightrock, Carbon Direct Capital, GenZero and Kibo Investments, has reached agreement to acquire U.K.-based sustainable aviation fuel developer Velocys in a recommended cash offer. The transaction includes a payment of 0.25 pence per Velocys share and up to $40 million of growth capital from Bidco to support Velocys’ medium-term plans; a £3.5 million secured bridging loan has also been provided by the Carbon Direct Fund to fund operations until closing.

Gryphon Investors Acquires Vetnique Labs

April 20, 2023

Consumer Products

Gryphon Investors, a San Francisco-based private equity firm, has acquired Vetnique Labs, a Naperville, Illinois-based pet health and wellness company. Gryphon will partner with founder and CEO James Bascharon (who will remain in role and retain a significant stake) to expand Vetnique’s product portfolio and geographic reach; financial terms were not disclosed.

Velocity Clinical Research Acquires Meridian Clinical Research

December 15, 2022

Healthcare Services

Velocity Clinical Research, a GHO-backed integrated research site organization, has acquired Meridian Clinical Research for an undisclosed amount. The deal creates the largest dedicated clinical research site organization globally (about 80 sites), expands Velocity's U.S. footprint to 25 states and adds Meridian's network of 35+ sites and experienced investigators and staff.

GHO Capital Acquires Velocity Clinical Research

July 15, 2021

Healthcare Services

Global Healthcare Opportunities (GHO) has acquired Durham-based Velocity Clinical Research from NaviMed Capital and other investors. GHO intends to support Velocity’s roll-up strategy of clinical trial sites, expand its integrated site model (including investment in technology and decentralized trial capabilities) and pursue further geographic expansion, including into Europe.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.